Ben Samelson Jones

Ben Samelson-Jones, MD, PhD is an Assistant Professor of Pediatrics and a member of the Gene Therapy and Vaccine (GTV) Graduate Program at the University of Pennsylvania. He is an attending pediatric hematologist and member of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia (CHOP). And he is the Associate Director of the Clinical In Vivo Gene Therapy group at CHOP.

He provides medical care for patients with blood diseases with a special interest in hemophilia and other bleeding disorders. He is a principal investigator on clinical gene therapy trials for hemophilia A and hemophilia B and has translational laboratory focused on developing novel treatments for bleeding disorders. His laboratory is supported by funding from the National Heart, Lung, and Blood Institute, the National Hemophilia Foundation, as well as by a number of sponsored research agreements with biotech partners. His research includes defining the biochemical mechanism of the hyperactivity of factor IX (FIX) Padua, which is used in all current gene transfer clinical trials for hemophilia B. He has published over 30 peer-reviewed papers including in The New England Journal of Medicine, Blood, and Molecular Therapy and filed for three patents. He is an abstract reviewer for the American Society of Hematology (ASH) and the International Society of Thrombosis and Haemostasis (ISTH) and is currently a member of the Translational Research Committee of the American Society of Gene and Cell Therapy (ASGCT).

He received his undergraduate degree in physics from Amherst College and his MD and PhD from Albert Einstein College of Medicine. He completed residency at the Children’s National Medical Center and fellowship at CHOP.